|
WO2021034796A1
|
|
Process for preparing an e-selectin inhibitor intermediate
|
|
WO2021021994A1
|
|
Use of highly potent multimeric e-selectin antagonists for treating sickle cell disease
|
|
WO2020219419A1
|
|
Multimeric pan–selectin antagonists
|
|
WO2020219417A1
|
|
Galactose-linked multimeric glycomimetic inhibitors of e-selectins, galectin-3, and/or cxcr4 chemokine receptors
|
|
WO2020139960A1
|
|
Galectin-3 inhibiting c-glycosides
|
|
WO2020139962A1
|
|
Heterobifunctional inhibitors of e-selectin and galectin-3
|
|
WO2020123435A2
|
|
Methods of treating hiv and aids and the elimination of latent reservoirs of hiv infection using selectin, galectin, and siglec antagonists
|
|
AU2019230013A1
|
|
Methods for treating acute myeloid leukemia and related conditions
|
|
AU2018395417A1
|
|
Heterobifunctional inhibitors of E-selectin and galectin-3
|
|
WO2019108750A1
|
|
Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
|
|
EP3596096A1
|
|
Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
|
|
EP3522931A1
|
|
Highly potent multimeric e-selectin antagonists
|
|
EP3497131A1
|
|
Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4
|
|
WO2017205269A1
|
|
Haloalkyl fucose-containing selectin antagonists
|
|
WO2017151708A1
|
|
Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
|
|
WO2017127422A1
|
|
Glycomimetic inhibitors of pa-il and pa-iil lectins
|
|
CA2950088A1
|
|
Heterobifunctional compounds having a triazole linker and e and/or p selectin binding affinity
|
|
CN108350077A
|
|
Generate monoclonal antibody, the method and composition of candidate stem cell and the method using the antibody and candidate stem cell
|
|
CN108289889A
|
|
The antibody of target on cancer stem cell and treatment invasive cancer
|
|
EP3331539A1
|
|
Methods for the mobilization and use of t-cells with enhanced reconstitution potential and life-span
|
